Validation of the graded prognostic assessment for Melanoma using molecular markers (Melanoma-molGPA)
Abstract: Background: It has been suggested to replace the diagnosis-specific graded prognostic assessment (DS-GPA, based on performance status and number of brain metastases) for patients with primary malignant melanoma with the new Melanoma-molGPA. The latter is a more complex assessment, which also includes BRAF mutation status, age and extracranial metastases. To test the performance of the Melanoma-molGPA, we performed a validation study of this new survival prediction tool.
Methods: A retrospective analysis of patients treated at two different academic institutions was performed. The four-tiered Melanoma-molGPA was calculated as suggested in the original study.
Results: Median overall survival was 5.4 months (95% confidence interval: 3.1 - 7.7 months). Median survival in the four prognostic classes was 2.1, 7.8, 11.8, and 18.0 months, respectively. The 1-year survival rates were 3%, 25%, 43%, and 80%, respectively. The difference between the Kaplan-Meier curves was significant (P = 0.0001, log-rank test).
Conclusions: The present survival outcomes support the use of the Melanoma-molGPA. However, survival was better in each of the four groups in the original study. Possible reasons include lead-time bias and different treatment policies
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
Journal of clinical medicine research. - 10, 3 (2018) , 178-181, ISSN: 1918-3011
- Schlagwort
-
Hirnmetastase
Melanom
- Ereignis
-
Veröffentlichung
- (wo)
-
Freiburg
- (wer)
-
Universität
- (wann)
-
2019
- DOI
-
10.14740/jocmr3248w
- URN
-
urn:nbn:de:bsz:25-freidok-1438969
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
25.03.2025, 13:44 MEZ
Datenpartner
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
Entstanden
- 2019
Ähnliche Objekte (12)
![10-Jahres-Letalität, Krankheitsprogress und behandlungsassoziierte Nebenwirkungen bei Männern mit lokalisiertem Prostatakarzinom aus der randomisierten, kontrollierten ProtecT-Studie, analysiert nach erhaltener Therapie : = [10-Year mortality, disease progression, and treatment-related side effects in men with localized prostate cancer from the ProtecT Randomised Controlled Trial, analyzed according to treatment received]](/assets/placeholder/searchResultMediaUnknown.png)